STAb-T19

N/A

Report date: 2026/03/20 20:03:07

Base Information

Drug NameSTAb-T19

Drug Alias NameSTAb-T19

ClassificationCell and gene therapy > Gene therapyBiologics > T cell engagersCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy

Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySpain

CombinationsNo

Global Highest StatusClinical

Highest Status in ChinaN/A

Originator CompaniesSTAb Therapeutics

China Registration ClassN/A

Develop Information

Active CompaniesSTAb Therapeutics

Inactive CompaniesN/A

Active IndicationsLymphoma, B-CellPrecursor B-Cell Lymphoblastic Leukemia-Lymphoma

Inactive IndicationsN/A

Other Information

ATC CodeN/A